HLS Therapeutics Inc.
HLS.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -6.61% | -10.23% | -9.46% | -5.85% | -1.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -6.61% | -10.23% | -9.46% | -5.85% | -1.42% |
| Cost of Revenue | 12.67% | 11.08% | 15.75% | 21.47% | 24.71% |
| Gross Profit | -12.23% | -15.87% | -15.65% | -12.15% | -7.10% |
| SG&A Expenses | -9.23% | -4.80% | -11.58% | -8.60% | -6.52% |
| Depreciation & Amortization | -24.99% | -28.87% | -27.55% | -20.99% | -13.97% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.54% | -12.42% | -14.17% | -9.55% | -5.36% |
| Operating Income | 39.72% | 25.73% | 36.39% | 27.01% | 22.93% |
| Income Before Tax | 50.52% | 43.96% | 38.04% | 22.10% | -8.09% |
| Income Tax Expenses | 1,662.84% | 1,597.43% | 1,019.23% | 3,492.66% | -13.97% |
| Earnings from Continuing Operations | 35.41% | 28.61% | 22.85% | 7.59% | -8.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.41% | 28.61% | 22.85% | 7.59% | -8.04% |
| EBIT | 39.72% | 25.73% | 36.39% | 27.01% | 22.93% |
| EBITDA | -16.65% | -30.38% | -21.63% | -17.09% | -7.78% |
| EPS Basic | 23.24% | 16.10% | 21.78% | 6.58% | -8.84% |
| Normalized Basic EPS | 6.01% | -3.37% | 8.39% | 3.51% | -1.92% |
| EPS Diluted | 22.01% | 15.01% | 21.67% | 6.97% | -8.13% |
| Normalized Diluted EPS | 6.01% | -3.37% | 8.39% | 3.51% | -1.92% |
| Average Basic Shares Outstanding | -2.07% | -2.28% | -1.37% | -1.15% | -0.84% |
| Average Diluted Shares Outstanding | -2.07% | -2.28% | -1.37% | -1.15% | -0.84% |
| Dividend Per Share | -- | -- | -98.41% | -98.80% | -73.72% |
| Payout Ratio | -- | -- | 1.00% | 1.00% | 0.77% |